Home › Companies › CRISPR THERAPEUTICS AG › 2025-2026

CRISPR THERAPEUTICS AG 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and CRISPR THERAPEUTICS AG’s Form 8-K (Item 5.07 on EDGAR). Page generated 02 October 2026.

53Reported items
517Asset managers
6,968Fund votes
2026-06-04Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore CRISPR THERAPEUTICS AG in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by CRISPR THERAPEUTICS AG

These tallies are CRISPR THERAPEUTICS AG’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

CRISPR THERAPEUTICS AG — official shareholder meeting results, meeting held 2026-06-04
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Samarth Kulkarni, Ph.D.	47,043,987	1,628,226	82,640	--	22,498,855	Majority: yes
Elect Director: Ali Behbahani, M.D.	35,498,392	13,174,523	81,938	--	22,498,855	Majority: yes
Elect Director: Maria Fardis, Ph.D.	47,804,457	874,207	76,189	--	22,498,855	Majority: yes
Elect Director: H. Edward Fleming Jr., M.D.	46,977,636	1,686,127	91,090	--	22,498,855	Majority: yes
Elect Director: Simeon J. George, M.D.	47,435,748	1,225,519	93,586	--	22,498,855	Majority: yes
Elect Director: John T. Greene	46,876,367	1,793,109	85,377	--	22,498,855	Majority: yes
Elect Director: Katherine A. High, M.D.	47,779,619	899,787	75,447	--	22,498,855	Majority: yes
Elect Director: Sandesh Mahatme, LL.M.	46,268,964	2,405,580	80,309	--	22,498,855	Majority: yes
Elect Director: Briggs W. Morrison, M.D.	46,013,911	2,659,681	81,261	--	22,498,855	Majority: yes
Elect Director: Christian Rommel, Ph.D.	47,802,202	872,050	80,601	--	22,498,855	Majority: yes
Elect Director: Douglas A. Treco, Ph.D.	44,359,453	4,317,384	78,016	--	22,498,855	Majority: yes
Elect Director: Ali Behbahani, M.D.	35,458,908	13,198,641	97,304	--	22,498,855	Majority: yes
Elect Director: H. Edward Fleming Jr., M.D.	46,322,476	2,341,513	90,864	--	22,498,855	Majority: yes
Elect Director: John T. Greene	46,319,646	2,326,146	109,061	--	22,498,855	Majority: yes
Elect Director: Briggs W. Morrison, M.D.	45,317,635	3,329,265	107,953	--	22,498,855	Majority: yes

Source: CRISPR THERAPEUTICS AG, Form 8-K — read the filing on EDGAR.

How asset managers voted at the CRISPR THERAPEUTICS AG 2025-2026 meeting

Each item below shows how the 517 asset managers that disclosed a CRISPR THERAPEUTICS AG vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of CRISPR THERAPEUTICS AG’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS UNDER U.S. SECURITIES LAW REQUIREMENTS.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-06-04.

Combines 7 wordings of this item as funds reported it.

53.2% fund support · no official result

FOR 53.1%AGAINST 46.8%

The 479 asset managers below cast 53.2% of the shares they voted on this item FOR (21,429,783 for, 18,856,139 against).

FOR: 21,429,783 (53.1%)AGAINST: 18,856,139 (46.8%)ABSTAIN: 1,151 (0.0%)NOT VOTED: 39,088 (0.1%)NO VOTE: 325 (0.0%)

Largest asset managers voting on “NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS UNDER U.S. SECURI” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
Capital Group	150	11,416,456	Against
ARK ETF Trust	9,776,043	0	For
T. Rowe Price	3,036,987	113,052	For
BlackRock	2,124,579	5,721	For
SR ONE CAPITAL MANAGEMENT, LP	2,038,763	0	For
Amova Asset Management Co., Ltd.	0	1,835,407	Against
Charles Schwab	0	1,114,256	Against
NEA Management Company, LLC	1,060,002	0	For
State Street	789,026	5,863	For
Loomis Sayles	0	550,073	Against
ARK Investment Management LLC	549,000	0	For
Vanguard	408,497	2,793	For
Northern Trust	0	403,138	Against
Fidelity	38,814	354,545	Against
Green Alpha Advisors, LLC	0	271,425	Against
Vestmark Advisory Solutions, Inc.	0	251,455	Against
ARK Venture Fund	171,926	0	For
WELLS FARGO CLEARING SERVICES, LLC	162,856	0	For
Versant Venture Management, LLC	148,831	0	For
MELLON INVESTMENTS Corp	146,580	0	For
RBC Capital Markets, LLC	0	140,405	Against
Equitable	13,278	122,735	Against
Lincoln Financial	65,390	69,768	Against
AMERICAN BEACON FUNDS	125,188	0	For
UBS	0	119,974	Against

Showing the 25 largest of 479 asset managers. See all 479 in the interactive database.

2. NON-BINDING ADVISORY VOTE ON THE 2025 COMPENSATION REPORT.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

91% fund support · no official result

FOR 91%9%

The 127 asset managers below cast 91% of the shares they voted on this item FOR (10,809,372 for, 1,129,384 against).

FOR: 10,809,372 (90.5%)AGAINST: 1,129,384 (9.5%)ABSTAIN: 1,073 (0.0%)

Largest asset managers voting on “NON-BINDING ADVISORY VOTE ON THE 2025 COMPENSATION REPORT.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
Capital Group	5,387,072	0	For
SR ONE CAPITAL MANAGEMENT, LP	2,038,763	0	For
T. Rowe Price	1,225,262	246	For
NEA Management Company, LLC	1,060,002	0	For
Charles Schwab	0	557,037	Against
Vanguard	286,372	1,394	For
State Street	198,049	0	For
Fidelity	38,814	138,929	Against
Versant Venture Management, LLC	148,831	0	For
Equitable	13,278	122,735	Against
Lincoln Financial	65,390	69,768	Against
AMERICAN BEACON FUNDS	125,188	0	For
American Century	59,438	0	For
RMB INVESTORS TRUST	0	37,600	Against
Northwestern Mutual	33,247	0	For
Guggenheim	0	32,826	Against
Investment Managers Series Trust II	31,000	0	For
Capitol Series Trust	0	22,300	Against
Global X	0	17,975	Against
JPMorgan	16,747	0	For
ETFis Series Trust I	0	16,046	Against
Ipswich Investment Management Co., Inc.	15,673	0	For
SEI	0	14,652	Against
ProShares	0	13,143	Against
TARGET PORTFOLIO TRUST	12,900	0	For

Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.

3. BINDING VOTE ON MAXIMUM EQUITY FOR MEMBERS OF THE BOARD OF DIRECTORS FROM THE 2026 ANNUAL GENERAL MEETING TO THE 2027 ANNUAL GENERAL MEETING OF SHAREHOLDERS.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

89% fund support · no official result

FOR 89%11%

The 103 asset managers below cast 89% of the shares they voted on this item FOR (10,604,996 for, 1,335,304 against).

FOR: 10,604,996 (88.8%)AGAINST: 1,335,304 (11.2%)

Largest asset managers voting on “BINDING VOTE ON MAXIMUM EQUITY FOR MEMBERS OF THE BOARD OF DIRECTORS FROM THE 2026 ANNUAL GENERAL MEETING TO T” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
Capital Group	5,387,072	0	For
SR ONE CAPITAL MANAGEMENT, LP	2,038,763	0	For
T. Rowe Price	1,225,508	0	For
NEA Management Company, LLC	1,060,002	0	For
Charles Schwab	0	557,037	Against
Vanguard	286,372	1,394	For
State Street	0	198,049	Against
Fidelity	177,743	0	For
Versant Venture Management, LLC	148,831	0	For
Equitable	13,278	122,735	Against
Lincoln Financial	6,490	128,668	Against
AMERICAN BEACON FUNDS	125,188	0	For
American Century	0	59,438	Against
RMB INVESTORS TRUST	0	37,600	Against
Northwestern Mutual	33,247	0	For
Guggenheim	0	32,826	Against
Investment Managers Series Trust II	31,000	0	For
Janney Montgomery Scott LLC	0	24,211	Against
Capitol Series Trust	0	22,300	Against
Global X	0	17,975	Against
JPMorgan	16,747	0	For
ETFis Series Trust I	0	16,046	Against
Ipswich Investment Management Co., Inc.	15,673	0	For
SEI	0	14,652	Against
ProShares	0	13,143	Against

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

4. Binding vote on maximum non- performance-related compensation for members of the Executive Committee from July 1, 2026 to June 30, 2027.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-06-04.

Combines 3 wordings of this item as funds reported it.

96% fund support · no official result

FOR 96%

The 103 asset managers below cast 96% of the shares they voted on this item FOR (11,505,333 for, 428,867 against).

FOR: 11,505,333 (96.4%)AGAINST: 428,867 (3.6%)

Largest asset managers voting on “Binding vote on maximum non- performance-related compensation for members of the Executive Committee from July” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
Capital Group	5,387,072	0	For
SR ONE CAPITAL MANAGEMENT, LP	2,038,763	0	For
T. Rowe Price	1,225,262	246	For
NEA Management Company, LLC	1,060,002	0	For
Charles Schwab	557,037	0	For
Vanguard	287,762	4	For
State Street	198,049	0	For
Fidelity	38,814	138,929	Against
Versant Venture Management, LLC	148,831	0	For
Equitable	71,923	64,090	For
Lincoln Financial	120,300	14,858	For
AMERICAN BEACON FUNDS	125,188	0	For
American Century	0	59,438	Against
RMB INVESTORS TRUST	0	37,600	Against
Northwestern Mutual	33,247	0	For
Guggenheim	0	32,826	Against
Investment Managers Series Trust II	31,000	0	For
Janney Montgomery Scott LLC	24,211	0	For
Capitol Series Trust	22,300	0	For
Global X	17,975	0	For
JPMorgan	16,747	0	For
ETFis Series Trust I	0	16,046	Against
SEI	14,652	0	For
ProShares	0	13,143	Against
TARGET PORTFOLIO TRUST	12,900	0	For

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

5. BINDING VOTE ON MAXIMUM VARIABLE COMPENSATION FOR MEMBERS OF THE EXECUTIVE COMMITTEE FOR THE CURRENT YEAR ENDING DECEMBER 31, 2026.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-06-04.

Combines 3 wordings of this item as funds reported it.

96% fund support · no official result

FOR 96%

The 103 asset managers below cast 96% of the shares they voted on this item FOR (11,505,633 for, 428,567 against).

FOR: 11,505,633 (96.4%)AGAINST: 428,567 (3.6%)

Largest asset managers voting on “BINDING VOTE ON MAXIMUM VARIABLE COMPENSATION FOR MEMBERS OF THE EXECUTIVE COMMITTEE FOR THE CURRENT YEAR ENDI” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
Capital Group	5,387,072	0	For
SR ONE CAPITAL MANAGEMENT, LP	2,038,763	0	For
T. Rowe Price	1,225,262	246	For
NEA Management Company, LLC	1,060,002	0	For
Charles Schwab	557,037	0	For
Vanguard	287,762	4	For
State Street	198,049	0	For
Fidelity	38,814	138,929	Against
Versant Venture Management, LLC	148,831	0	For
Equitable	71,923	64,090	For
Lincoln Financial	120,300	14,858	For
AMERICAN BEACON FUNDS	125,188	0	For
American Century	0	59,438	Against
RMB INVESTORS TRUST	0	37,600	Against
Northwestern Mutual	33,247	0	For
Guggenheim	0	32,826	Against
Investment Managers Series Trust II	31,000	0	For
Janney Montgomery Scott LLC	24,211	0	For
Capitol Series Trust	22,300	0	For
Global X	17,975	0	For
JPMorgan	16,747	0	For
ETFis Series Trust I	0	16,046	Against
SEI	14,652	0	For
ProShares	0	13,143	Against
TARGET PORTFOLIO TRUST	12,900	0	For

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

6. BINDING VOTE ON MAXIMUM EQUITY FOR MEMBERS OF THE EXECUTIVE COMMITTEE FROM THE 2026 ANNUAL GENERAL MEETING TO THE 2027 ANNUAL GENERAL MEETING OF SHAREHOLDERS.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

45% fund support · no official result

FOR 45%AGAINST 55%

The 101 asset managers below cast 45% of the shares they voted on this item FOR (5,327,746 for, 6,596,460 against).

FOR: 5,327,746 (44.7%)AGAINST: 6,596,460 (55.3%)

Largest asset managers voting on “BINDING VOTE ON MAXIMUM EQUITY FOR MEMBERS OF THE EXECUTIVE COMMITTEE FROM THE 2026 ANNUAL GENERAL MEETING TO ” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
Capital Group	0	5,387,072	Against
SR ONE CAPITAL MANAGEMENT, LP	2,038,763	0	For
T. Rowe Price	1,225,262	246	For
NEA Management Company, LLC	1,060,002	0	For
Charles Schwab	0	557,037	Against
Vanguard	286,372	1,394	For
State Street	198,049	0	For
Fidelity	38,814	138,929	Against
Versant Venture Management, LLC	148,831	0	For
Equitable	13,278	122,735	Against
Lincoln Financial	65,390	69,768	Against
AMERICAN BEACON FUNDS	125,188	0	For
American Century	0	59,438	Against
RMB INVESTORS TRUST	0	37,600	Against
Northwestern Mutual	33,247	0	For
Guggenheim	0	32,826	Against
Investment Managers Series Trust II	31,000	0	For
Janney Montgomery Scott LLC	0	24,211	Against
Capitol Series Trust	0	22,300	Against
Global X	0	17,975	Against
JPMorgan	16,747	0	For
ETFis Series Trust I	0	16,046	Against
SEI	0	14,652	Against
ProShares	0	13,143	Against
TARGET PORTFOLIO TRUST	12,900	0	For

Showing the 25 largest of 101 asset managers. See all 101 in the interactive database.

7. Approval of the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan.

COMPENSATION

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

99% fund support · no official result

FOR 99%

The 80 asset managers below cast 99% of the shares they voted on this item FOR (20,488,269 for, 255,763 against).

FOR: 20,488,269 (98.8%)AGAINST: 255,763 (1.2%)

Largest asset managers voting on “Approval of the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
Capital Group	5,387,072	0	For
T. Rowe Price	1,225,508	0	For
NEA Management Company, LLC	1,060,002	0	For
BlackRock	908,144	0	For
Charles Schwab	557,037	0	For
Vanguard	287,763	3	For
State Street	198,049	0	For
Fidelity	177,743	0	For
ARK Venture Fund	171,926	0	For
Equitable	136,013	0	For
Lincoln Financial	120,300	14,858	For
AMERICAN BEACON FUNDS	125,188	0	For
Natixis	76,100	0	For
American Century	0	59,438	Against
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
RMB INVESTORS TRUST	0	37,600	Against
Northwestern Mutual	33,247	0	For
Guggenheim	0	32,826	Against
Investment Managers Series Trust II	31,000	0	For
Capitol Series Trust	22,300	0	For
Global X	17,975	0	For
John Hancock	134	16,953	Against
JPMorgan	16,747	0	For

Showing the 25 largest of 80 asset managers. See all 80 in the interactive database.

8. RE-ELECTION OF THE MEMBERS OF THE COMPENSATION COMMITTEE: BRIGGS W. MORRISON, M.D.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

94% fund support · no official result

FOR 94%

The 77 asset managers below cast 94% of the shares they voted on this item FOR (11,106,682 for, 664,822 against).

FOR: 11,106,682 (94.4%)AGAINST: 664,822 (5.6%)

Largest asset managers voting on “RE-ELECTION OF THE MEMBERS OF THE COMPENSATION COMMITTEE: BRIGGS W. MORRISON, M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
BlackRock	908,144	0	For
Charles Schwab	0	557,037	Against
ARK Venture Fund	171,926	0	For
Natixis	0	76,100	Against
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
Investment Managers Series Trust II	31,000	0	For
Global X	17,975	0	For
John Hancock	17,087	0	For
JPMorgan	0	16,747	Against
Ipswich Investment Management Co., Inc.	15,673	0	For
SEI	14,652	0	For
TARGET PORTFOLIO TRUST	12,900	0	For
Russell Investments	11,658	0	For
Venerable Variable Insurance Trust	6,757	0	For
Lincoln Financial	0	6,490	Against
Loomis Sayles	0	5,310	Against
UNITED CAPITAL FINANCIAL ADVISORS, LLC	4,945	0	For
QUANTITATIVE MASTER SERIES LLC	3,800	0	For
EA Series Trust	3,562	0	For
Vanguard	3,282	3	For
HOLDERNESS INVESTMENTS CO	2,469	0	For
SevenBridge Financial Group, LLC	2,150	0	For
Allianz	0	2,134	Against

Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.

9. Approval of the Swiss management report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2025.

AUDIT-RELATED

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 73 asset managers below cast 100% of the shares they voted on this item FOR (19,676,269 for, 0 against).

FOR: 19,676,269 (100.0%)

Largest asset managers voting on “Approval of the Swiss management report, the consolidated financial statements and the statutory financial sta” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Vote
ARK ETF Trust	9,776,043	For
Capital Group	5,387,072	For
T. Rowe Price	1,225,508	For
BlackRock	908,144	For
Charles Schwab	557,037	For
Vanguard	287,766	For
State Street	198,049	For
Fidelity	177,743	For
ARK Venture Fund	171,926	For
Equitable	136,013	For
Lincoln Financial	135,158	For
AMERICAN BEACON FUNDS	125,188	For
Natixis	76,100	For
American Century	59,438	For
Clough Global Equity Fund	41,270	For
Bridge Builder Trust	40,875	For
RMB INVESTORS TRUST	37,600	For
Northwestern Mutual	33,247	For
Guggenheim	32,826	For
Investment Managers Series Trust II	31,000	For
Capitol Series Trust	22,300	For
Global X	17,975	For
John Hancock	17,087	For
JPMorgan	16,747	For
ETFis Series Trust I	16,046	For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

10. Approval of the appropriation of financial results.

AUDIT-RELATED

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 73 asset managers below cast 100% of the shares they voted on this item FOR (19,676,269 for, 0 against).

FOR: 19,676,269 (100.0%)

Largest asset managers voting on “Approval of the appropriation of financial results.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Vote
ARK ETF Trust	9,776,043	For
Capital Group	5,387,072	For
T. Rowe Price	1,225,508	For
BlackRock	908,144	For
Charles Schwab	557,037	For
Vanguard	287,766	For
State Street	198,049	For
Fidelity	177,743	For
ARK Venture Fund	171,926	For
Equitable	136,013	For
Lincoln Financial	135,158	For
AMERICAN BEACON FUNDS	125,188	For
Natixis	76,100	For
American Century	59,438	For
Clough Global Equity Fund	41,270	For
Bridge Builder Trust	40,875	For
RMB INVESTORS TRUST	37,600	For
Northwestern Mutual	33,247	For
Guggenheim	32,826	For
Investment Managers Series Trust II	31,000	For
Capitol Series Trust	22,300	For
Global X	17,975	For
John Hancock	17,087	For
JPMorgan	16,747	For
ETFis Series Trust I	16,046	For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

11. Discharge of the members of the Board of Directors and the Executive Committee.

AUDIT-RELATED

Meeting held 2026-06-04.

100% fund support · no official result

FOR 100%

The 73 asset managers below cast 100% of the shares they voted on this item FOR (19,676,269 for, 0 against).

FOR: 19,676,269 (100.0%)

Largest asset managers voting on “Discharge of the members of the Board of Directors and the Executive Committee.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Vote
ARK ETF Trust	9,776,043	For
Capital Group	5,387,072	For
T. Rowe Price	1,225,508	For
BlackRock	908,144	For
Charles Schwab	557,037	For
Vanguard	287,766	For
State Street	198,049	For
Fidelity	177,743	For
ARK Venture Fund	171,926	For
Equitable	136,013	For
Lincoln Financial	135,158	For
AMERICAN BEACON FUNDS	125,188	For
Natixis	76,100	For
American Century	59,438	For
Clough Global Equity Fund	41,270	For
Bridge Builder Trust	40,875	For
RMB INVESTORS TRUST	37,600	For
Northwestern Mutual	33,247	For
Guggenheim	32,826	For
Investment Managers Series Trust II	31,000	For
Capitol Series Trust	22,300	For
Global X	17,975	For
John Hancock	17,087	For
JPMorgan	16,747	For
ETFis Series Trust I	16,046	For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

12. Re-election of the members to the Board of Directors and the Chairman: Re-election of Samarth Kulkarni, Ph.D., as member and Chairman

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 47,043,987AGAINST: 1,628,226

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Samarth Kulkarni, Ph.D.”): 47,043,987 for, 1,628,226 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,385,506 outstanding shares: 48.8% for, 2% against (50.5% of the company cast a for/against vote).

The 73 asset managers below cast 98% of the shares they voted on this item FOR (19,375,839 for, 300,475 against).

FOR 98%

FOR: 19,375,839 (98.5%)AGAINST: 300,475 (1.5%)

Largest asset managers voting on “Re-election of the members to the Board of Directors and the Chairman: Re-election of Samarth Kulkarni, Ph.D.,” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
Capital Group	5,387,072	0	For
T. Rowe Price	1,225,508	0	For
BlackRock	908,144	0	For
Charles Schwab	557,037	0	For
Vanguard	286,376	1,390	For
State Street	198,049	0	For
Fidelity	177,743	0	For
ARK Venture Fund	171,926	0	For
Equitable	13,278	122,735	Against
Lincoln Financial	78,121	57,037	For
AMERICAN BEACON FUNDS	125,188	0	For
Natixis	0	76,100	Against
American Century	59,438	0	For
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
RMB INVESTORS TRUST	37,600	0	For
Northwestern Mutual	33,247	0	For
Guggenheim	32,826	0	For
Investment Managers Series Trust II	31,000	0	For
Capitol Series Trust	0	22,300	Against
Global X	17,975	0	For
John Hancock	17,087	0	For
JPMorgan	16,747	0	For
ETFis Series Trust I	16,046	0	For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

13. Re-election of Maria Fardis, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 47,804,457AGAINST: 874,207

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Maria Fardis, Ph.D.”): 47,804,457 for, 874,207 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,385,506 outstanding shares: 49.6% for, 1.0% against (50.5% of the company cast a for/against vote).

The 73 asset managers below cast 99% of the shares they voted on this item FOR (19,477,676 for, 198,637 against).

FOR 99%

FOR: 19,477,676 (99.0%)AGAINST: 198,637 (1.0%)

Largest asset managers voting on “Re-election of Maria Fardis, Ph.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
Capital Group	5,387,072	0	For
T. Rowe Price	1,225,508	0	For
BlackRock	908,144	0	For
Charles Schwab	557,037	0	For
Vanguard	286,708	1,057	For
State Street	198,049	0	For
Fidelity	177,743	0	For
ARK Venture Fund	171,926	0	For
Equitable	77,368	58,645	For
Lincoln Financial	80,248	54,910	For
AMERICAN BEACON FUNDS	125,188	0	For
Natixis	0	76,100	Against
American Century	59,438	0	For
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
RMB INVESTORS TRUST	37,600	0	For
Northwestern Mutual	33,247	0	For
Guggenheim	32,826	0	For
Investment Managers Series Trust II	31,000	0	For
Capitol Series Trust	22,300	0	For
Global X	17,975	0	For
John Hancock	17,087	0	For
JPMorgan	16,747	0	For
ETFis Series Trust I	16,046	0	For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

14. Re-election of Simeon J. George, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 47,435,748AGAINST: 1,225,519

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Simeon J. George, M.D.”): 47,435,748 for, 1,225,519 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,385,506 outstanding shares: 49.2% for, 1% against (50.5% of the company cast a for/against vote).

The 73 asset managers below cast 99% of the shares they voted on this item FOR (19,455,052 for, 221,262 against).

FOR 99%

FOR: 19,455,052 (98.9%)AGAINST: 221,262 (1.1%)

Largest asset managers voting on “Re-election of Simeon J. George, M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
Capital Group	5,387,072	0	For
T. Rowe Price	1,225,508	0	For
BlackRock	908,144	0	For
Charles Schwab	557,037	0	For
Vanguard	287,765	1	For
State Street	198,049	0	For
Fidelity	177,743	0	For
ARK Venture Fund	171,926	0	For
Equitable	77,368	58,645	For
Lincoln Financial	73,758	61,400	For
AMERICAN BEACON FUNDS	125,188	0	For
Natixis	0	76,100	Against
American Century	59,438	0	For
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
RMB INVESTORS TRUST	37,600	0	For
Northwestern Mutual	33,247	0	For
Guggenheim	32,826	0	For
Investment Managers Series Trust II	31,000	0	For
Capitol Series Trust	22,300	0	For
Global X	17,975	0	For
John Hancock	17,087	0	For
JPMorgan	0	16,747	Against
ETFis Series Trust I	16,046	0	For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

15. Re-election of Katherine A. High, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 47,779,619AGAINST: 899,787

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Katherine A. High, M.D.”): 47,779,619 for, 899,787 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,385,506 outstanding shares: 49.6% for, 1.0% against (50.5% of the company cast a for/against vote).

The 73 asset managers below cast 99% of the shares they voted on this item FOR (19,471,816 for, 204,498 against).

FOR 99%

FOR: 19,471,816 (99.0%)AGAINST: 204,498 (1.0%)

Largest asset managers voting on “Re-election of Katherine A. High, M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
Capital Group	5,387,072	0	For
T. Rowe Price	1,225,508	0	For
BlackRock	908,144	0	For
Charles Schwab	557,037	0	For
Vanguard	287,766	0	For
State Street	198,049	0	For
Fidelity	177,743	0	For
ARK Venture Fund	171,926	0	For
Equitable	77,368	58,645	For
Lincoln Financial	80,248	54,910	For
AMERICAN BEACON FUNDS	125,188	0	For
Natixis	0	76,100	Against
American Century	59,438	0	For
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
RMB INVESTORS TRUST	37,600	0	For
Northwestern Mutual	33,247	0	For
Guggenheim	32,826	0	For
Investment Managers Series Trust II	31,000	0	For
Capitol Series Trust	22,300	0	For
Global X	17,975	0	For
John Hancock	17,087	0	For
JPMorgan	16,747	0	For
ETFis Series Trust I	16,046	0	For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

16. Re-election of Sandesh Mahatme, LL.M.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 46,268,964AGAINST: 2,405,580

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Sandesh Mahatme, LL.M.”): 46,268,964 for, 2,405,580 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,385,506 outstanding shares: 48.0% for, 2% against (50.5% of the company cast a for/against vote).

The 73 asset managers below cast 96% of the shares they voted on this item FOR (18,847,181 for, 829,133 against).

FOR 96%

FOR: 18,847,181 (95.8%)AGAINST: 829,133 (4.2%)

Largest asset managers voting on “Re-election of Sandesh Mahatme, LL.M.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
Capital Group	5,387,072	0	For
T. Rowe Price	1,225,508	0	For
BlackRock	908,144	0	For
Charles Schwab	0	557,037	Against
Vanguard	286,376	1,390	For
State Street	198,049	0	For
Fidelity	177,743	0	For
ARK Venture Fund	171,926	0	For
Equitable	77,368	58,645	For
Lincoln Financial	80,248	54,910	For
AMERICAN BEACON FUNDS	125,188	0	For
Natixis	0	76,100	Against
American Century	59,438	0	For
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
RMB INVESTORS TRUST	37,600	0	For
Northwestern Mutual	33,247	0	For
Guggenheim	32,826	0	For
Investment Managers Series Trust II	31,000	0	For
Capitol Series Trust	0	22,300	Against
Global X	0	17,975	Against
John Hancock	17,087	0	For
JPMorgan	16,747	0	For
ETFis Series Trust I	16,046	0	For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

17. Re-election of Christian Rommel, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 47,802,202AGAINST: 872,050

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Christian Rommel, Ph.D.”): 47,802,202 for, 872,050 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,385,506 outstanding shares: 49.6% for, 1.0% against (50.5% of the company cast a for/against vote).

The 73 asset managers below cast 99% of the shares they voted on this item FOR (19,479,291 for, 197,023 against).

FOR 99%

FOR: 19,479,291 (99.0%)AGAINST: 197,023 (1.0%)

Largest asset managers voting on “Re-election of Christian Rommel, Ph.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
Capital Group	5,387,072	0	For
T. Rowe Price	1,225,508	0	For
BlackRock	908,144	0	For
Charles Schwab	557,037	0	For
Vanguard	287,766	0	For
State Street	198,049	0	For
Fidelity	177,743	0	For
ARK Venture Fund	171,926	0	For
Equitable	77,368	58,645	For
Lincoln Financial	80,248	54,910	For
AMERICAN BEACON FUNDS	125,188	0	For
Natixis	0	76,100	Against
American Century	59,438	0	For
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
RMB INVESTORS TRUST	37,600	0	For
Northwestern Mutual	33,247	0	For
Guggenheim	32,826	0	For
Investment Managers Series Trust II	31,000	0	For
Capitol Series Trust	22,300	0	For
Global X	17,975	0	For
John Hancock	17,087	0	For
JPMorgan	16,747	0	For
ETFis Series Trust I	16,046	0	For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

18. Re-election of Douglas A. Treco, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 3 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 44,359,453AGAINST: 4,317,384

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Douglas A. Treco, Ph.D.”): 44,359,453 for, 4,317,384 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,385,506 outstanding shares: 46.0% for, 4% against (50.5% of the company cast a for/against vote).

The 73 asset managers below cast 93% of the shares they voted on this item FOR (18,251,923 for, 1,424,390 against).

FOR 93%7%

FOR: 18,251,923 (92.8%)AGAINST: 1,424,390 (7.2%)

Largest asset managers voting on “Re-election of Douglas A. Treco, Ph.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
Capital Group	5,387,072	0	For
T. Rowe Price	1,225,508	0	For
BlackRock	46,415	861,729	Against
Charles Schwab	557,037	0	For
Vanguard	286,706	1,059	For
State Street	0	198,049	Against
Fidelity	138,929	38,814	For
ARK Venture Fund	171,926	0	For
Equitable	64,090	71,923	Against
Lincoln Financial	21,348	113,810	Against
AMERICAN BEACON FUNDS	125,188	0	For
Natixis	0	76,100	Against
American Century	59,438	0	For
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	0	40,875	Against
RMB INVESTORS TRUST	37,600	0	For
Northwestern Mutual	33,247	0	For
Guggenheim	32,826	0	For
Investment Managers Series Trust II	31,000	0	For
Capitol Series Trust	22,300	0	For
Global X	17,975	0	For
John Hancock	17,087	0	For
JPMorgan	16,747	0	For
ETFis Series Trust I	16,046	0	For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

19. Re-election of the independent voting rights representative.

DIRECTOR ELECTIONS

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 72 asset managers below cast 100% of the shares they voted on this item FOR (19,676,244 for, 0 against).

FOR: 19,676,244 (100.0%)

Largest asset managers voting on “Re-election of the independent voting rights representative.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Vote
ARK ETF Trust	9,776,043	For
Capital Group	5,387,072	For
T. Rowe Price	1,225,508	For
BlackRock	908,144	For
Charles Schwab	557,037	For
Vanguard	287,766	For
State Street	198,049	For
Fidelity	177,743	For
ARK Venture Fund	171,926	For
Equitable	136,013	For
Lincoln Financial	135,158	For
AMERICAN BEACON FUNDS	125,188	For
Natixis	76,100	For
American Century	59,438	For
Clough Global Equity Fund	41,270	For
Bridge Builder Trust	40,875	For
RMB INVESTORS TRUST	37,600	For
Northwestern Mutual	33,247	For
Guggenheim	32,826	For
Investment Managers Series Trust II	31,000	For
Capitol Series Trust	22,300	For
Global X	17,975	For
John Hancock	17,087	For
JPMorgan	16,747	For
ETFis Series Trust I	16,046	For

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

20. Re-election of the auditors.

AUDIT-RELATED

Meeting held 2026-06-04.

100% fund support · no official result

FOR 99.8%

The 72 asset managers below cast 100% of the shares they voted on this item FOR (19,653,944 for, 0 against).

FOR: 19,653,944 (99.9%)ABSTAIN: 22,300 (0.1%)

Largest asset managers voting on “Re-election of the auditors.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Abstain	Vote
ARK ETF Trust	9,776,043	0	For
Capital Group	5,387,072	0	For
T. Rowe Price	1,225,508	0	For
BlackRock	908,144	0	For
Charles Schwab	557,037	0	For
Vanguard	287,766	0	For
State Street	198,049	0	For
Fidelity	177,743	0	For
ARK Venture Fund	171,926	0	For
Equitable	136,013	0	For
Lincoln Financial	135,158	0	For
AMERICAN BEACON FUNDS	125,188	0	For
Natixis	76,100	0	For
American Century	59,438	0	For
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
RMB INVESTORS TRUST	37,600	0	For
Northwestern Mutual	33,247	0	For
Guggenheim	32,826	0	For
Investment Managers Series Trust II	31,000	0	For
Capitol Series Trust	0	22,300	Abstain
Global X	17,975	0	For
John Hancock	17,087	0	For
JPMorgan	16,747	0	For
ETFis Series Trust I	16,046	0	For

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

21. Transact any other business that may properly come before the 2026 Annual General Meeting or any adjournment or postponement thereof.

OTHER

Meeting held 2026-06-04.

79% fund support · no official result

FOR 79%AGAINST 21%

The 72 asset managers below cast 79% of the shares they voted on this item FOR (15,559,697 for, 4,116,546 against).

FOR: 15,559,697 (79.1%)AGAINST: 4,116,546 (20.9%)

Largest asset managers voting on “Transact any other business that may properly come before the 2026 Annual General Meeting or any adjournment o” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
Capital Group	5,387,072	0	For
T. Rowe Price	0	1,225,508	Against
BlackRock	0	908,144	Against
Charles Schwab	0	557,037	Against
Vanguard	829	286,936	Against
State Street	0	198,049	Against
Fidelity	0	177,743	Against
ARK Venture Fund	171,926	0	For
Equitable	0	136,013	Against
Lincoln Financial	6,490	128,668	Against
AMERICAN BEACON FUNDS	125,188	0	For
Natixis	0	76,100	Against
American Century	0	59,438	Against
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	0	40,875	Against
RMB INVESTORS TRUST	0	37,600	Against
Northwestern Mutual	0	33,247	Against
Guggenheim	0	32,826	Against
Investment Managers Series Trust II	31,000	0	For
Capitol Series Trust	0	22,300	Against
Global X	0	17,975	Against
John Hancock	0	17,087	Against
JPMorgan	16,747	0	For
ETFis Series Trust I	0	16,046	Against

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

22. Approval of an increase to the Company's capital band.

OTHER

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 72 asset managers below cast 99.9% of the shares they voted on this item FOR (19,672,682 for, 3,562 against).

FOR: 19,672,682 (100.0%)AGAINST: 3,562 (0.0%)

Largest asset managers voting on “Approval of an increase to the Company's capital band.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Vote
ARK ETF Trust	9,776,043	For
Capital Group	5,387,072	For
T. Rowe Price	1,225,508	For
BlackRock	908,144	For
Charles Schwab	557,037	For
Vanguard	287,766	For
State Street	198,049	For
Fidelity	177,743	For
ARK Venture Fund	171,926	For
Equitable	136,013	For
Lincoln Financial	135,158	For
AMERICAN BEACON FUNDS	125,188	For
Natixis	76,100	For
American Century	59,438	For
Clough Global Equity Fund	41,270	For
Bridge Builder Trust	40,875	For
RMB INVESTORS TRUST	37,600	For
Northwestern Mutual	33,247	For
Guggenheim	32,826	For
Investment Managers Series Trust II	31,000	For
Capitol Series Trust	22,300	For
Global X	17,975	For
John Hancock	17,087	For
JPMorgan	16,747	For
ETFis Series Trust I	16,046	For

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

23. Approval of an increase to the conditional share capital for the conversion of bonds and similar debt instruments.

CAPITAL STRUCTURE

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

99% fund support · no official result

FOR 99%

The 72 asset managers below cast 99% of the shares they voted on this item FOR (19,416,938 for, 259,306 against).

FOR: 19,416,938 (98.7%)AGAINST: 259,306 (1.3%)

Largest asset managers voting on “Approval of an increase to the conditional share capital for the conversion of bonds and similar debt instrume” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
Capital Group	5,387,072	0	For
T. Rowe Price	1,225,508	0	For
BlackRock	908,144	0	For
Charles Schwab	557,037	0	For
Vanguard	287,765	1	For
State Street	0	198,049	Against
Fidelity	177,743	0	For
ARK Venture Fund	171,926	0	For
Equitable	136,013	0	For
Lincoln Financial	76,258	58,900	For
AMERICAN BEACON FUNDS	125,188	0	For
Natixis	76,100	0	For
American Century	59,438	0	For
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
RMB INVESTORS TRUST	37,600	0	For
Northwestern Mutual	33,247	0	For
Guggenheim	32,826	0	For
Investment Managers Series Trust II	31,000	0	For
Capitol Series Trust	22,300	0	For
Global X	17,975	0	For
John Hancock	17,087	0	For
JPMorgan	16,747	0	For
ETFis Series Trust I	16,046	0	For

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

24. Binding vote on maximum non- performance-related compensation for members of the Board of Directors from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 68 asset managers below cast 100% of the shares they voted on this item FOR (4,027,143 for, 0 against).

FOR: 4,027,143 (100.0%)

Largest asset managers voting on “Binding vote on maximum non- performance-related compensation for members of the Board of Directors from the 2” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Vote
SR ONE CAPITAL MANAGEMENT, LP	2,038,763	For
NEA Management Company, LLC	1,060,002	For
Charles Schwab	557,037	For
Versant Venture Management, LLC	148,831	For
Investment Managers Series Trust II	31,000	For
Janney Montgomery Scott LLC	24,211	For
Capitol Series Trust	22,300	For
Global X	17,975	For
JPMorgan	16,747	For
Ipswich Investment Management Co., Inc.	15,673	For
SEI	14,652	For
TARGET PORTFOLIO TRUST	12,900	For
Russell Investments	11,658	For
Jasper Ridge Partners, L.P.	9,539	For
Venerable Variable Insurance Trust	6,757	For
Lincoln Financial	6,490	For
UNITED CAPITAL FINANCIAL ADVISORS, LLC	4,945	For
Vanguard	3,285	For
HOLDERNESS INVESTMENTS CO	2,469	For
SevenBridge Financial Group, LLC	2,150	For
Nationwide	1,990	For
Atlantic Union Bankshares Corp	1,566	For
Waverly Advisors, LLC	1,532	For
Bogart Wealth, LLC	1,250	For
Sound View Wealth Advisors Group, LLC	1,214	For

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

25. Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2025 Compensation Report: Binding vote on maximum non-performance-related compensation for members of the Board of Directors from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders.

COMPENSATION

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 59 asset managers below cast 100% of the shares they voted on this item FOR (18,971,158 for, 0 against).

FOR: 18,971,158 (100.0%)

Largest asset managers voting on “Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory v” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Vote
ARK ETF Trust	9,776,043	For
Capital Group	5,387,072	For
T. Rowe Price	1,225,508	For
BlackRock	908,144	For
Vanguard	284,481	For
State Street	198,049	For
Fidelity	177,743	For
ARK Venture Fund	171,926	For
Equitable	136,013	For
Lincoln Financial	128,668	For
AMERICAN BEACON FUNDS	125,188	For
Natixis	76,100	For
American Century	59,438	For
Clough Global Equity Fund	41,270	For
Bridge Builder Trust	40,875	For
RMB INVESTORS TRUST	37,600	For
Northwestern Mutual	33,247	For
Guggenheim	32,826	For
John Hancock	17,087	For
ETFis Series Trust I	16,046	For
ProShares	13,143	For
AIG/SunAmerica	9,576	For
Direxion Shares ETF Trust	9,396	For
Calvert	7,475	For
Franklin Templeton	6,651	For

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

26. Re-election of H. Edward Fleming, Jr., M.D.

DIRECTOR ELECTIONS

Meeting held 2026-06-04.

Combines 4 wordings of this item as funds reported it.

96% fund support · no official result

FOR 96%

The 57 asset managers below cast 96% of the shares they voted on this item FOR (8,290,485 for, 347,060 against).

FOR: 8,290,485 (96.0%)AGAINST: 347,060 (4.0%)

Largest asset managers voting on “Re-election of H. Edward Fleming, Jr., M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
Capital Group	5,387,072	0	For
T. Rowe Price	1,225,508	0	For
Charles Schwab	557,037	0	For
Vanguard	286,706	1,059	For
State Street	198,049	0	For
Fidelity	38,814	138,929	Against
Equitable	13,278	122,735	Against
Lincoln Financial	71,631	63,527	For
AMERICAN BEACON FUNDS	125,188	0	For
American Century	59,438	0	For
RMB INVESTORS TRUST	37,600	0	For
Northwestern Mutual	33,247	0	For
Guggenheim	32,826	0	For
Investment Managers Series Trust II	31,000	0	For
Capitol Series Trust	22,300	0	For
Global X	17,975	0	For
JPMorgan	0	16,747	Against
ETFis Series Trust I	16,046	0	For
SEI	14,652	0	For
ProShares	13,143	0	For
TARGET PORTFOLIO TRUST	12,900	0	For
Russell Investments	11,658	0	For
AIG/SunAmerica	9,576	0	For
Jasper Ridge Partners, L.P.	9,539	0	For
Direxion Shares ETF Trust	9,396	0	For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

27. Re-election of Ali Behbahani, M.D.

DIRECTOR ELECTIONS

Meeting held 2026-06-04.

Combines 3 wordings of this item as funds reported it.

67% fund support · no official result

FOR 67%AGAINST 33%

The 56 asset managers below cast 67% of the shares they voted on this item FOR (5,806,524 for, 2,821,483 against).

FOR: 5,806,524 (67.3%)AGAINST: 2,821,483 (32.7%)

Largest asset managers voting on “Re-election of Ali Behbahani, M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
Capital Group	5,387,072	0	For
T. Rowe Price	246	1,225,262	Against
Charles Schwab	0	557,037	Against
Vanguard	1,890	285,876	Against
State Street	198,049	0	For
Fidelity	0	177,743	Against
Equitable	0	136,013	Against
Lincoln Financial	58,900	76,258	Against
AMERICAN BEACON FUNDS	125,188	0	For
American Century	0	59,438	Against
RMB INVESTORS TRUST	0	37,600	Against
Northwestern Mutual	0	33,247	Against
Guggenheim	0	32,826	Against
Investment Managers Series Trust II	31,000	0	For
Capitol Series Trust	0	22,300	Against
Global X	0	17,975	Against
JPMorgan	0	16,747	Against
ETFis Series Trust I	0	16,046	Against
SEI	0	14,652	Against
ProShares	0	13,143	Against
TARGET PORTFOLIO TRUST	0	12,900	Against
Russell Investments	0	11,658	Against
AIG/SunAmerica	0	9,576	Against
Direxion Shares ETF Trust	0	9,396	Against
Venerable Variable Insurance Trust	0	8,432	Against

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

28. Re-election of John T. Greene

DIRECTOR ELECTIONS

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

96% fund support · no official result

FOR 96%

The 56 asset managers below cast 96% of the shares they voted on this item FOR (8,280,915 for, 347,092 against).

FOR: 8,280,915 (96.0%)AGAINST: 347,092 (4.0%)

Largest asset managers voting on “Re-election of John T. Greene” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
Capital Group	5,387,072	0	For
T. Rowe Price	1,225,508	0	For
Charles Schwab	557,037	0	For
Vanguard	286,375	1,391	For
State Street	198,049	0	For
Fidelity	38,814	138,929	Against
Equitable	13,278	122,735	Against
Lincoln Financial	71,631	63,527	For
AMERICAN BEACON FUNDS	125,188	0	For
American Century	59,438	0	For
RMB INVESTORS TRUST	37,600	0	For
Northwestern Mutual	33,247	0	For
Guggenheim	32,826	0	For
Investment Managers Series Trust II	31,000	0	For
Capitol Series Trust	22,300	0	For
Global X	17,975	0	For
JPMorgan	0	16,747	Against
ETFis Series Trust I	16,046	0	For
SEI	14,652	0	For
ProShares	13,143	0	For
TARGET PORTFOLIO TRUST	12,900	0	For
Russell Investments	11,658	0	For
AIG/SunAmerica	9,576	0	For
Direxion Shares ETF Trust	9,396	0	For
Venerable Variable Insurance Trust	8,432	0	For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

29. Re-election of Briggs W. Morrison, M.D.

DIRECTOR ELECTIONS

Meeting held 2026-06-04.

93% fund support · no official result

FOR 93%7%

The 55 asset managers below cast 93% of the shares they voted on this item FOR (8,022,929 for, 605,008 against).

FOR: 8,022,929 (93.0%)AGAINST: 605,008 (7.0%)

Largest asset managers voting on “Re-election of Briggs W. Morrison, M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
Capital Group	5,387,072	0	For
T. Rowe Price	1,225,508	0	For
Charles Schwab	557,037	0	For
Vanguard	287,764	2	For
State Street	0	198,049	Against
Fidelity	38,814	138,929	Against
Equitable	13,278	122,735	Against
Lincoln Financial	12,731	122,427	Against
AMERICAN BEACON FUNDS	125,188	0	For
American Century	59,438	0	For
RMB INVESTORS TRUST	37,600	0	For
Northwestern Mutual	33,247	0	For
Guggenheim	32,826	0	For
Investment Managers Series Trust II	31,000	0	For
Capitol Series Trust	22,300	0	For
Global X	17,975	0	For
JPMorgan	0	16,747	Against
ETFis Series Trust I	16,046	0	For
SEI	14,652	0	For
ProShares	13,143	0	For
TARGET PORTFOLIO TRUST	12,900	0	For
Russell Investments	11,658	0	For
AIG/SunAmerica	9,576	0	For
Direxion Shares ETF Trust	9,396	0	For
Venerable Variable Insurance Trust	8,432	0	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

30. Re-election of the members of the Compensation Committee: Re-election of Ali Behbahani, M.D.

DIRECTOR ELECTIONSCORPORATE GOVERNANCE

Meeting held 2026-06-04.

73% fund support · no official result

FOR 73%AGAINST 27%

The 41 asset managers below cast 73% of the shares they voted on this item FOR (5,771,944 for, 2,148,787 against).

FOR: 5,771,944 (72.9%)AGAINST: 2,148,787 (27.1%)

Largest asset managers voting on “Re-election of the members of the Compensation Committee: Re-election of Ali Behbahani, M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
Capital Group	5,387,072	0	For
T. Rowe Price	246	1,225,262	Against
Vanguard	0	284,481	Against
State Street	198,049	0	For
Fidelity	0	177,743	Against
Equitable	0	136,013	Against
Lincoln Financial	58,900	69,768	Against
AMERICAN BEACON FUNDS	125,188	0	For
American Century	0	59,438	Against
RMB INVESTORS TRUST	0	37,600	Against
Northwestern Mutual	0	33,247	Against
Guggenheim	0	32,826	Against
ETFis Series Trust I	0	16,046	Against
ProShares	0	13,143	Against
AIG/SunAmerica	0	9,576	Against
Direxion Shares ETF Trust	0	9,396	Against
Calvert	0	7,475	Against
Franklin Templeton	0	6,651	Against
Voya	0	5,728	Against
Allspring	0	3,864	Against
Morgan Stanley	0	3,509	Against
Blackstone Alternative Investment Funds	0	3,400	Against
Nationwide	0	2,575	Against
PENN SERIES FUNDS INC	2,332	0	For
TIAA	0	1,795	Against

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

31. Re-election of the members of the Compensation Committee: Ali Behbahani, M.D.

DIRECTOR ELECTIONS

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

86% fund support · no official result

FOR 86%AGAINST 14%

The 35 asset managers below cast 86% of the shares they voted on this item FOR (10,041,772 for, 1,691,297 against).

FOR: 10,041,772 (85.6%)AGAINST: 1,691,297 (14.4%)

Largest asset managers voting on “Re-election of the members of the Compensation Committee: Ali Behbahani, M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
BlackRock	0	908,144	Against
Charles Schwab	0	557,037	Against
ARK Venture Fund	171,926	0	For
Natixis	0	76,100	Against
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	0	40,875	Against
Investment Managers Series Trust II	31,000	0	For
Global X	0	17,975	Against
John Hancock	0	17,087	Against
JPMorgan	0	16,747	Against
SEI	0	14,652	Against
TARGET PORTFOLIO TRUST	12,900	0	For
Russell Investments	0	11,658	Against
Venerable Variable Insurance Trust	0	6,757	Against
Lincoln Financial	0	6,490	Against
Loomis Sayles	0	5,310	Against
QUANTITATIVE MASTER SERIES LLC	0	3,800	Against
EA Series Trust	3,562	0	For
Vanguard	1,890	1,395	For
Allianz	0	2,134	Against
Nationwide	0	1,990	Against
Formidable Asset Management, LLC	1,190	0	For
New York Life	0	1,173	Against
Brighthouse	0	1,001	Against

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

32. Re-election of the members of the Compensation Committee - H. Edward Fleming, Jr., M.D.

DIRECTOR ELECTIONS

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

99.0% fund support · no official result

FOR 99.0%

The 25 asset managers below cast 99.0% of the shares they voted on this item FOR (10,996,916 for, 109,398 against).

FOR: 10,996,916 (99.0%)AGAINST: 109,398 (1.0%)

Largest asset managers voting on “Re-election of the members of the Compensation Committee - H. Edward Fleming, Jr., M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
BlackRock	908,144	0	For
ARK Venture Fund	171,926	0	For
Natixis	0	76,100	Against
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
Investment Managers Series Trust II	31,000	0	For
John Hancock	17,087	0	For
JPMorgan	0	16,747	Against
Lincoln Financial	0	6,490	Against
Loomis Sayles	0	5,310	Against
QUANTITATIVE MASTER SERIES LLC	3,800	0	For
EA Series Trust	3,562	0	For
Allianz	0	2,134	Against
Formidable Asset Management, LLC	1,190	0	For
Vanguard	20	1,059	Against
Brighthouse	0	1,001	Against
REYNOLDS FUNDS INC	700	0	For
Jackson National	511	0	For
Crewe Advisors LLC	350	0	For
Legacy Capital Wealth Partners, LLC	0	300	Against
Amplify ETF Trust	0	257	Against
Roberts Wealth Advisors, LLC	200	0	For
WILSHIRE MUTUAL FUNDS INC	197	0	For
Jacob Funds Inc.	41	0	For

33. Re-election of the members of the Compensation Committee - John T. Greene

DIRECTOR ELECTIONS

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

99.0% fund support · no official result

FOR 99.0%

The 25 asset managers below cast 99.0% of the shares they voted on this item FOR (10,998,530 for, 107,784 against).

FOR: 10,998,530 (99.0%)AGAINST: 107,784 (1.0%)

Largest asset managers voting on “Re-election of the members of the Compensation Committee - John T. Greene” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
BlackRock	908,144	0	For
ARK Venture Fund	171,926	0	For
Natixis	0	76,100	Against
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
Investment Managers Series Trust II	31,000	0	For
John Hancock	17,087	0	For
JPMorgan	0	16,747	Against
Lincoln Financial	0	6,490	Against
Loomis Sayles	0	5,310	Against
QUANTITATIVE MASTER SERIES LLC	3,800	0	For
EA Series Trust	3,562	0	For
Allianz	0	2,134	Against
Formidable Asset Management, LLC	1,190	0	For
Vanguard	1,077	2	For
Brighthouse	0	1,001	Against
REYNOLDS FUNDS INC	700	0	For
Jackson National	511	0	For
Crewe Advisors LLC	350	0	For
Legacy Capital Wealth Partners, LLC	300	0	For
Amplify ETF Trust	257	0	For
Roberts Wealth Advisors, LLC	200	0	For
WILSHIRE MUTUAL FUNDS INC	197	0	For
Jacob Funds Inc.	41	0	For

34. Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2025 Compensation Report - Binding vote on maximum equity for members of the Board of Directors from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders.

COMPENSATION

Meeting held 2026-06-04.

99% fund support · no official result

FOR 99%

The 17 asset managers below cast 99% of the shares they voted on this item FOR (10,901,198 for, 147,109 against).

FOR: 10,901,198 (98.7%)AGAINST: 147,109 (1.3%)

Largest asset managers voting on “Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory v” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
BlackRock	861,729	46,415	For
ARK Venture Fund	171,926	0	For
Natixis	0	76,100	Against
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
John Hancock	134	16,953	Against
Loomis Sayles	0	5,310	Against
QUANTITATIVE MASTER SERIES LLC	3,800	0	For
EA Series Trust	3,562	0	For
Allianz	0	2,134	Against
REYNOLDS FUNDS INC	700	0	For
Jackson National	511	0	For
Crewe Advisors LLC	350	0	For
Amplify ETF Trust	257	0	For
WILSHIRE MUTUAL FUNDS INC	0	197	Against
Jacob Funds Inc.	41	0	For

35. Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2025 Compensation Report - Binding vote on maximum equity for members of the Executive Committee from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders.

COMPENSATION

Meeting held 2026-06-04.

99.0% fund support · no official result

FOR 99.0%

The 17 asset managers below cast 99.0% of the shares they voted on this item FOR (10,947,613 for, 100,694 against).

FOR: 10,947,613 (99.1%)AGAINST: 100,694 (0.9%)

Largest asset managers voting on “Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory v” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
BlackRock	908,144	0	For
ARK Venture Fund	171,926	0	For
Natixis	0	76,100	Against
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
John Hancock	134	16,953	Against
Loomis Sayles	0	5,310	Against
QUANTITATIVE MASTER SERIES LLC	3,800	0	For
EA Series Trust	3,562	0	For
Allianz	0	2,134	Against
REYNOLDS FUNDS INC	700	0	For
Jackson National	511	0	For
Crewe Advisors LLC	350	0	For
Amplify ETF Trust	257	0	For
WILSHIRE MUTUAL FUNDS INC	0	197	Against
Jacob Funds Inc.	41	0	For

36. Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2025 Compensation Report - Binding vote on maximum non- performance-related compensation for members of the Executive Committee from July 1, 2026 to June 30, 2027.

COMPENSATION

Meeting held 2026-06-04.

99.8% fund support · no official result

FOR 99.8%

The 17 asset managers below cast 99.8% of the shares they voted on this item FOR (11,029,220 for, 19,087 against).

FOR: 11,029,220 (99.8%)AGAINST: 19,087 (0.2%)

Largest asset managers voting on “Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory v” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
BlackRock	908,144	0	For
ARK Venture Fund	171,926	0	For
Natixis	76,100	0	For
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
John Hancock	134	16,953	Against
Loomis Sayles	5,310	0	For
QUANTITATIVE MASTER SERIES LLC	3,800	0	For
EA Series Trust	3,562	0	For
Allianz	0	2,134	Against
REYNOLDS FUNDS INC	700	0	For
Jackson National	511	0	For
Crewe Advisors LLC	350	0	For
Amplify ETF Trust	257	0	For
WILSHIRE MUTUAL FUNDS INC	197	0	For
Jacob Funds Inc.	41	0	For

37. Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2025 Compensation Report - Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2026.

COMPENSATION

Meeting held 2026-06-04.

99.8% fund support · no official result

FOR 99.8%

The 17 asset managers below cast 99.8% of the shares they voted on this item FOR (11,029,220 for, 19,087 against).

FOR: 11,029,220 (99.8%)AGAINST: 19,087 (0.2%)

Largest asset managers voting on “Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory v” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
BlackRock	908,144	0	For
ARK Venture Fund	171,926	0	For
Natixis	76,100	0	For
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
John Hancock	134	16,953	Against
Loomis Sayles	5,310	0	For
QUANTITATIVE MASTER SERIES LLC	3,800	0	For
EA Series Trust	3,562	0	For
Allianz	0	2,134	Against
REYNOLDS FUNDS INC	700	0	For
Jackson National	511	0	For
Crewe Advisors LLC	350	0	For
Amplify ETF Trust	257	0	For
WILSHIRE MUTUAL FUNDS INC	197	0	For
Jacob Funds Inc.	41	0	For

38. Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2025 Compensation Report - Non-binding advisory vote on the 2025 Compensation Report.

COMPENSATION

Meeting held 2026-06-04.

99.1% fund support · no official result

FOR 99.1%

The 17 asset managers below cast 99.1% of the shares they voted on this item FOR (12,164,048 for, 106,415 against).

FOR: 12,164,048 (99.1%)AGAINST: 106,415 (0.9%)

Largest asset managers voting on “Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory v” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
BlackRock	2,124,579	5,721	For
ARK Venture Fund	171,926	0	For
Natixis	0	76,100	Against
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
John Hancock	134	16,953	Against
Loomis Sayles	0	5,310	Against
QUANTITATIVE MASTER SERIES LLC	3,800	0	For
EA Series Trust	3,562	0	For
Allianz	0	2,134	Against
REYNOLDS FUNDS INC	700	0	For
Jackson National	511	0	For
Crewe Advisors LLC	350	0	For
Amplify ETF Trust	257	0	For
WILSHIRE MUTUAL FUNDS INC	0	197	Against
Jacob Funds Inc.	41	0	For

39. Re-election of the members to the Board of Directors and the Chairman. Ali Behbahani, M.D.

DIRECTOR ELECTIONS

Meeting held 2026-06-04.

90% fund support · no official result

FOR 90%10%

The 17 asset managers below cast 90% of the shares they voted on this item FOR (9,993,892 for, 1,054,415 against).

FOR: 9,993,892 (90.5%)AGAINST: 1,054,415 (9.5%)

Largest asset managers voting on “Re-election of the members to the Board of Directors and the Chairman. Ali Behbahani, M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
BlackRock	0	908,144	Against
ARK Venture Fund	171,926	0	For
Natixis	0	76,100	Against
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	0	40,875	Against
John Hancock	0	17,087	Against
Loomis Sayles	0	5,310	Against
QUANTITATIVE MASTER SERIES LLC	0	3,800	Against
EA Series Trust	3,562	0	For
Allianz	0	2,134	Against
REYNOLDS FUNDS INC	700	0	For
Jackson National	0	511	Against
Crewe Advisors LLC	350	0	For
Amplify ETF Trust	0	257	Against
WILSHIRE MUTUAL FUNDS INC	0	197	Against
Jacob Funds Inc.	41	0	For

40. Re-election of the members to the Board of Directors and the Chairman. Briggs W. Morrison, M.D.

DIRECTOR ELECTIONS

Meeting held 2026-06-04.

99.2% fund support · no official result

FOR 99.2%

The 17 asset managers below cast 99.2% of the shares they voted on this item FOR (10,964,763 for, 83,544 against).

FOR: 10,964,763 (99.2%)AGAINST: 83,544 (0.8%)

Largest asset managers voting on “Re-election of the members to the Board of Directors and the Chairman. Briggs W. Morrison, M.D.” at CRISPR THERAPEUTICS AG, 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	9,776,043	0	For
BlackRock	908,144	0	For
ARK Venture Fund	171,926	0	For
Natixis	0	76,100	Against
Clough Global Equity Fund	41,270	0	For
Bridge Builder Trust	40,875	0	For
John Hancock	17,087	0	For
Loomis Sayles	0	5,310	Against
QUANTITATIVE MASTER SERIES LLC	3,800	0	For
EA Series Trust	3,562	0	For
Allianz	0	2,134	Against
REYNOLDS FUNDS INC	700	0	For
Jackson National	511	0	For
Crewe Advisors LLC	350	0	For
Amplify ETF Trust	257	0	For
WILSHIRE MUTUAL FUNDS INC	197	0	For
Jacob Funds Inc.	41	0	For

Showing the 40 reported items with the widest manager coverage, of 53 in total. View every item.

Largest CRISPR THERAPEUTICS AG shareholders voting in 2025-2026

Ranked by the number of CRISPR THERAPEUTICS AG shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 96,385,506 shares outstanding at the time of that meeting.

Top CRISPR THERAPEUTICS AG shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Capital Group	11.84%
2	ARK ETF Trust	10.14%
3	T. Rowe Price	3.27%
4	BlackRock	2.21%
5	SR ONE CAPITAL MANAGEMENT, LP	2.12%
6	Amova Asset Management Co., Ltd.	1.90%
7	Charles Schwab	1.16%
8	NEA Management Company, LLC	1.10%
9	State Street	0.82%
10	Loomis Sayles	0.57%

Reported CRISPR THERAPEUTICS AG ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

CRISPR THERAPEUTICS AG beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
ARK Investment Management LLC	11.74%	13G
BlackRock	7.97%	13F
ORBIS INVESTMENT MANAGEMENT LTD	5.64%	13G
Capital World Investors	5.11%	13G
State Street	4.13%	13F
Geode Capital	2.47%	13F
Vanguard Group	2.35%	13F
Simeon J. George, M.D.	2.27%	DEF14A
FMR (Fidelity)	2.03%	13F
Samarth Kulkarni, Ph.D.	1.66%	DEF14A

Percentages above are of 96,385,506 shares outstanding, as reported by CRISPR THERAPEUTICS AG on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CRISPR THERAPEUTICS AG’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At CRISPR THERAPEUTICS AG's shareholder meeting held 2026-06-04, in the 2025-2026 proxy season, 517 asset managers reported how they voted in their SEC Form N-PX filings, covering 6,968 separate fund positions. Their filings are grouped here into 53 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. CRISPR THERAPEUTICS AG's own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS… — the reporting funds cast 53.2% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

CRISPR THERAPEUTICS AG proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).